Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
COPENHAGEN - Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.
(Reporting by Stine Jacobsen and Bhanvi Satija, editing by Anna Ringstrom )
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published June 8, 2026 at 12:41 AM.